

DEPOSITARY RECEIPTS

November 23, 2016

NEW DR ANNOUNCEMENT

Motif Bio Plc

Motif Bio is a clinical stage biopharmaceutical company based in the United Kingdom. The Company specializes in the development of novel antibiotics designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria. The Company's predominant product Iclaprim is being developed for the treatment of the most common and serious bacterial infections such as acute bacterial skin and skin structure infections and hospital acquired bacterial pneumonia (HABP). The Company is also engaged in discussions with pharmaceutical companies and universities to build a pipeline of innovative antibiotics targeting Gram positive and Gram negative bacteria.

DR Name:	Motif Bio
Effective Date:	November 23, 2016
Country of Incorporation:	United Kingdom
Exchange:	NASDAQ Stock Market
Type of ADR Program:	Sponsored - Level III
Ticker Symbol:	MTFB
CUSIP Number:	619784101
Ratio (DR:ORD):	1 : 20
Underlying Share Description:	Ordinary
Industry Classification:	Pharma. & Biotech.
Custodian(s) :	The Bank of New York Mellon

To learn more about ADRs and issuer programs, please call our marketing desks:

New York

Ravi Davis / Rick Maehr
DR Broker Liaison
adrdesk@bnymellon.com
+1 212 815 2267

London

Jacek Jankowski
DR Broker Liaison
jacek.jankowski@bnymellon.com
+44 207 163 7427

Depository Receipts are not insured by the FDIC or any other government agency, are not deposits or other obligations of, and are not guaranteed by BNY Mellon and are subject to investment risks including possible loss of principal amount invested.

This announcement and the information contained herein is provided for general informational purposes only. BNY Mellon does not warrant or guarantee the accuracy, timeliness or completeness of this information. We provide no advice or recommendation or endorsement with respect to any company or securities. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities. An offering is made by means of a prospectus only. BNY Mellon is regulated by the FSA.

DEPOSITARY RECEIPTS

